Navigation Links
Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
Date:4/24/2008

thout limitation, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS" in our Annual Report on Form 10-K for the year ended December 31, 2007, which was filed with the Securities and Exchange Commission on February 29, 2008. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Progenics Pharmaceuticals, Inc., of Tarrytown, NY, is a biopharma
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Wyeth to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
2. Wyeth Sets Webcast And Conference Call For 2008 First Quarter Earnings
3. Wyeth To Appeal Arkansas Hormone Therapy Trial Verdicts
4. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
5. Wyeth Announces Executive Change in Finance Organization
6. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
7. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
9. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
10. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
11. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 AACC ... to the 2015 AACC Annual Meeting & Clinical ... from July 26–30. The meeting showcased revolutionary advancements ... the ability of healthcare providers to diagnose patients ... effective medical treatment. As of ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... field clinical study of its canine osteoarthritis stem cell product, currently under development ... City, KS) and will be marketed in the US by Aratana. This product, ...
(Date:7/30/2015)... ST. LOUIS, July 30, 2015 ... period in 2014) , Reported sales were $697 ... of 2014.  Sales grew organically by 8%, and changes ... Recent acquisitions increased sales by 1%. , By ... 8% in Applied and 11% in SAFC Commercial. ...
(Date:7/29/2015)... 30, 2015 Sanofi, un ... ses résultats pour le premier semestre 2015. Le ... résultats. Visionner l,interview vidéo et lire ... Au sommaire de l,interview :  ... de croissance - Diabète ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... for 15 minutes, couldn't imagine the influence the Internet, blogging, social ... these tools, everyone can have their 15 minutes - but just ... is about all anyone has time for these days, at least ... reminded of this after coming back from a near three-week holiday ...
... the lead cancer drug candidate of Madison's Quintessence Biosciences ... Food and Drug Aministration for being tested on cancer ... meeting of the American Association for Cancer Research , ... scale and applied in safe doses, the company announced. , ...
... Madison, Wis . - Mithridion, Inc ., a biopharmaceutical ... of Alzheimer's disease, has closed an additional $1.2 million of ... , ,The latest round of funding brings the total equity ... above the company's initial funding target. Mithridion will use the ...
Cached Biology Technology:On the Web, attention spans shrink, the need for value rises 2On the Web, attention spans shrink, the need for value rises 3Quintessence Biosciences advances cancer drug 2Alzheimer's drug developer lands $1.2M in venture funding 2Alzheimer's drug developer lands $1.2M in venture funding 3
(Date:7/30/2015)... 2015 Cellecta, Inc., a U.S.-based provider ... and biomarker discovery, announced the release of its ... all human protein coding genes. CRISPR technology enables ... gene,s function. Cellecta,s new Human Whole Genome CRISPR ... so that researchers can investigate in a single ...
(Date:7/23/2015)... (NASDAQ: AWRE ), a leading supplier of biometrics software ... ended June 30, 2015.  Revenue for the ... 33% compared to $6.8 million in the same quarter last ... $0.3 million, or $0.01 per diluted share, which compared to ... period a year ago.  Lower revenue and ...
(Date:7/21/2015)... OXFORD, Connecticut , July 21, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... the Wocket® smart wallet, announces that it has ... Tokenization System and Method. This ... that not only authorizes an account, but also ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... yourself with a blanket to stave off the shivers? ... help alleviate shivering in patients who have been cooled ... or dangerously high fevers are often cooled to reduce ... aid healing. Unfortunately, cooling induces a natural and familiar ...
... Tiny flying machines can be used for everything ... simply making smaller versions of planes and helicopters ... Carolina State University are mimicking nature,s small flyers ... maneuverability and performance. Small flyers, or micro-aerial ...
... from the British Antarctic Survey have collected individuals from a ... subjected them to increasing levels of water temperature to learn ... that they are likely to experience in the future. The ... really close to their upper temperature range, and that further ...
Cached Biology News:Robo-bats with metal muscles may be next generation of remote control flyers 2
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
MAb to Desmoplakin I & II Desmoplakin I & II...
BD Biocoat Matrigel Matrix Thin Layer 35 mm Culture Dishes...
... of ICE-family proteases/caspases initiates apoptosis in mammalian ... Detection Kit provides a simple and convenient ... flow cytometry in intact cells. The ... aspartate residues linked to rhodamine 110 (D2R), ...
Biology Products: